MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
"Triple Helix" Innovation Model
4. Triple Helix _ Capture Strategies
Triple Helix Open Innovation
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Michigan
Vericel Corporation (NASDAQ:VCEL), formerly, Aastrom Biosciences Inc. (NASDAQ: ASTM)
Organization & Developments: Vericel
Parents
Vericel Corporation (NASDAQ:VCEL), formerly, Aastrom Biosciences Inc. (NASDAQ: ASTM)
Children
*Aastrom’s approach involves withdrawing a patient’s bone marrow cells, incubating them in a proprietary process at its Ann Arbor facility, and spurring growth of adult stem cells and progenitor cells that promote healing
*CLI is a severe form of cardiovascular disease in the legs, known as peripheral artery disease, in which blood vessels get so clogged up that doctors are forced to amputate
*Epicel is a permanent skin replacement for patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.
*MACI is a third generation autologous cellularized scaffold product that is used to repair single or multiple symptomatic, full-thickness cartilage defects of an adult's knee, with or without bone involvement.
*Multicell therapy for patients with critical limb ischemia (CLI) who have no other treatment options.
*The company currently markets two cell therapy products in the United States: MACI and Epicel.
*Vericel designs and manufactures autologous cell-based therapies for patients with serious diseases and conditions
2011: Aastrom Enters Final-Stage Trial With Stem-Cell Therapy for CLI Patients (2011)
2019: Revisiting Vericel_seekingalpha.com
2019: Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns
2020: MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
2021: FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop
2021: Vericel: A Leader In Cell-Based Therapy_seekingalpha.com
2022: Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A Buy_ seekingalpha.com
2023: Vericel: Aggressive Growth In 2023_seekingalpha.com
2024: Vericel Corporation: Hard To Justify Current Valuation_ seekingalpha.com
2025: Vericel Corporation: Moving From Sell To Neutral
2025: Vericel: Scalable Growth With Strong Margins
Jumps
*Key People: Vericel
Finance & Acquisitions: Vericel